Nyxoah (Nyxoah) Institutional Ownership : 7.50% (As of Jun. 08, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Nyxoah Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nyxoah's institutional ownership is 7.50%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nyxoah's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nyxoah's Float Percentage Of Total Shares Outstanding is 53.18%.

Nyxoah Institutional Ownership Historical Data

The historical data trend for Nyxoah's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyxoah Institutional Ownership Chart

Nyxoah Historical Data

The historical data trend for Nyxoah can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	9.00	8.96	8.85	8.74	8.39	8.62	8.81	9.23	8.99	7.50

Nyxoah Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Nyxoah (Nyxoah) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (NAS:NYXH) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

5YI:Germany NYXH:Belgium

Address

Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435

Website

https://www.nyxoah.com

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.